Evidence
ManagedCareCGM.com Presents: Continuous Glucose Monitoring in Managed Care: Emerging Evidence, Quality Trends, and Policy Implications
August 11, 2026Population Health CE Activities
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.5 credit hours available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: January 31, 2028
Click Here to Begin
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe evolving guideline recommendations for CGM across diabetes populations
- Evaluate clinical, real-world, and economic evidence supporting CGM use
- Assess implications of CGM for HEDIS/Stars performance, coverage decisions, and population health strategies
Expert Faculty
Hannah Berg, PharmD
Associate Director, PDL Strategy
UnitedHealthcare
Jamie Chan, PharmD
President/CEO
Elevare Healthcare Consulting, LLC
Charlie Dragovich
Principal
Stractical Solutions LLC
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP
Co-Director of Endocrine Disorders in Pregnancy
Director of Education and Training in Diabetes Technology
Cleveland Clinic Endocrinology & Metabolism Institute
Jaime Murillo, MD
SVP, CMO, Medical Affairs
UnitedHealthcare
This continuing education activity is supported by an independent educational grant from Dexcom Medical Affairs.
May 18, 2026Clinical Outcomes Economic Outcomes Guidelines / Policy / Population Health
In this Managed Healthcare Executive Between The Lines series, diabetes and managed care experts examine the clinical and economic impact of continuous glucose monitoring in diabetes care, delivering key insights for patients, providers, and payers.
LEARN MOREContinuous Glucose Monitoring at Hospital Discharge: Evidence, Implementation, and Value for Health Systems
May 5, 2026CGM Technology and Digital Health Population Health CGM Best Practices
This AJMC Profiles in Care article highlights best practices and real‑world insights from health systems implementing CGM at hospital discharge, including early clinical and operational outcomes relevant to payers and health system decision‑makers.
LEARN MOREExploratory Study of Selected Stakeholder Insights Into Continuous Glucose Monitoring in T2D With Risk-Sharing Agreements
December 17, 2025Coverage and Benefit Design Article / Publication
The article highlights how expanding access to continuous glucose monitoring (CGM) within risk-sharing agreements can improve glycemic outcomes and support value-based diabetes care, particularly for patients with poorly controlled type 2 diabetes. Real-world data from Ohio demonstrated rapid HbA1c reductions and high HEDIS target attainment when CGM was paired with reduced prior authorization and interdisciplinary care. An expert payer-provider panel recommended focusing risk-based CGM programs on non–insulin-treated patients with HbA1c >8%, using HbA1c and emerging CGM-derived metrics for performance measurement, and leveraging team-based models to reduce utilization and address health equity.
LEARN MOREDecember 17, 2025CGM Technology and Digital Health Article / Publication / CGM Best Practices
CGM initiation at hospital discharge is a practical way to support safer transitions of care, improve post-discharge glycemic management, and reduce preventable healthcare utilization. Early experience with structured protocols shows this approach is feasible and well-received by both patients and providers. This article shares an implementation pathway adapted from the Johns Hopkins Medicine CGM Hospital Discharge protocol.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Initiation and persistence of CGM use (>270 days/year) was associated with a significantly greater A1c reduction at 12 months (-1.52%) versus no CGM, regardless of therapy. Adding a GLP-1, SGLT2i, or insulin with CGM resulted in additional significant A1c reduction. These results highlight the broad benefits of sustained CGM use across different medication types, including for individuals not using insulin.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Early detection and management of gestational diabetes (GDM) benefits both mother and infants. For women with early GDM, Dexcom CGM improved maternal and neonatal complications, including lower unscheduled caesarean sections, preterm deliveries, large-for-gestational age neonates, and NICU admissions, compared to self-monitoring of blood glucose (SMBG).
LEARN MOREThe future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
October 20, 2025Population Health Article / Publication / Population Health
The article explores how expanding access to continuous glucose monitoring (CGM) for individuals with type 2 diabetes—especially those not using insulin—can lead to improved clinical outcomes and reduced healthcare costs. It presents peer-led best practices and underscores the value of integrating CGM into primary care, supported by real-world evidence. It highlights some of the latest evidence highlighting CGM’s benefits in lowering emergency department visits and optimizing medication use, while advocating for broader coverage and streamlined access to diabetes technology.
LEARN MOREImproved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
ManagedCareCGM.com Presents: Continuous Glucose Monitoring in Managed Care: Emerging Evidence, Quality Trends, and Policy Implications
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.5 credit hours available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: January 31, 2028
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe evolving guideline recommendations for CGM across diabetes populations
- Evaluate clinical, real-world, and economic evidence supporting CGM use
- Assess implications of CGM for HEDIS/Stars performance, coverage decisions, and population health strategies
Expert Faculty
Hannah Berg, PharmD
Associate Director, PDL Strategy
UnitedHealthcare
Jamie Chan, PharmD
President/CEO
Elevare Healthcare Consulting, LLC
Charlie Dragovich
Principal
Stractical Solutions LLC
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP
Co-Director of Endocrine Disorders in Pregnancy
Director of Education and Training in Diabetes Technology
Cleveland Clinic Endocrinology & Metabolism Institute
Jaime Murillo, MD
SVP, CMO, Medical Affairs
UnitedHealthcare
This continuing education activity is supported by an independent educational grant from Dexcom Medical Affairs.
May 18, 2026Clinical Outcomes Economic Outcomes Guidelines / Policy / Population Health
In this Managed Healthcare Executive Between The Lines series, diabetes and managed care experts examine the clinical and economic impact of continuous glucose monitoring in diabetes care, delivering key insights for patients, providers, and payers.
LEARN MOREContinuous Glucose Monitoring at Hospital Discharge: Evidence, Implementation, and Value for Health Systems
May 5, 2026CGM Technology and Digital Health Population Health CGM Best Practices
This AJMC Profiles in Care article highlights best practices and real‑world insights from health systems implementing CGM at hospital discharge, including early clinical and operational outcomes relevant to payers and health system decision‑makers.
LEARN MOREExploratory Study of Selected Stakeholder Insights Into Continuous Glucose Monitoring in T2D With Risk-Sharing Agreements
December 17, 2025Coverage and Benefit Design Article / Publication
The article highlights how expanding access to continuous glucose monitoring (CGM) within risk-sharing agreements can improve glycemic outcomes and support value-based diabetes care, particularly for patients with poorly controlled type 2 diabetes. Real-world data from Ohio demonstrated rapid HbA1c reductions and high HEDIS target attainment when CGM was paired with reduced prior authorization and interdisciplinary care. An expert payer-provider panel recommended focusing risk-based CGM programs on non–insulin-treated patients with HbA1c >8%, using HbA1c and emerging CGM-derived metrics for performance measurement, and leveraging team-based models to reduce utilization and address health equity.
LEARN MOREDecember 17, 2025CGM Technology and Digital Health Article / Publication / CGM Best Practices
CGM initiation at hospital discharge is a practical way to support safer transitions of care, improve post-discharge glycemic management, and reduce preventable healthcare utilization. Early experience with structured protocols shows this approach is feasible and well-received by both patients and providers. This article shares an implementation pathway adapted from the Johns Hopkins Medicine CGM Hospital Discharge protocol.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Initiation and persistence of CGM use (>270 days/year) was associated with a significantly greater A1c reduction at 12 months (-1.52%) versus no CGM, regardless of therapy. Adding a GLP-1, SGLT2i, or insulin with CGM resulted in additional significant A1c reduction. These results highlight the broad benefits of sustained CGM use across different medication types, including for individuals not using insulin.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Early detection and management of gestational diabetes (GDM) benefits both mother and infants. For women with early GDM, Dexcom CGM improved maternal and neonatal complications, including lower unscheduled caesarean sections, preterm deliveries, large-for-gestational age neonates, and NICU admissions, compared to self-monitoring of blood glucose (SMBG).
LEARN MOREThe future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
October 20, 2025Population Health Article / Publication / Population Health
The article explores how expanding access to continuous glucose monitoring (CGM) for individuals with type 2 diabetes—especially those not using insulin—can lead to improved clinical outcomes and reduced healthcare costs. It presents peer-led best practices and underscores the value of integrating CGM into primary care, supported by real-world evidence. It highlights some of the latest evidence highlighting CGM’s benefits in lowering emergency department visits and optimizing medication use, while advocating for broader coverage and streamlined access to diabetes technology.
LEARN MOREImproved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
In this Managed Healthcare Executive Between The Lines series, diabetes and managed care experts examine the clinical and economic impact of continuous glucose monitoring in diabetes care, delivering key insights for patients, providers, and payers.
LEARN MOREContinuous Glucose Monitoring at Hospital Discharge: Evidence, Implementation, and Value for Health Systems
May 5, 2026CGM Technology and Digital Health Population Health CGM Best Practices
This AJMC Profiles in Care article highlights best practices and real‑world insights from health systems implementing CGM at hospital discharge, including early clinical and operational outcomes relevant to payers and health system decision‑makers.
LEARN MOREExploratory Study of Selected Stakeholder Insights Into Continuous Glucose Monitoring in T2D With Risk-Sharing Agreements
December 17, 2025Coverage and Benefit Design Article / Publication
The article highlights how expanding access to continuous glucose monitoring (CGM) within risk-sharing agreements can improve glycemic outcomes and support value-based diabetes care, particularly for patients with poorly controlled type 2 diabetes. Real-world data from Ohio demonstrated rapid HbA1c reductions and high HEDIS target attainment when CGM was paired with reduced prior authorization and interdisciplinary care. An expert payer-provider panel recommended focusing risk-based CGM programs on non–insulin-treated patients with HbA1c >8%, using HbA1c and emerging CGM-derived metrics for performance measurement, and leveraging team-based models to reduce utilization and address health equity.
LEARN MOREDecember 17, 2025CGM Technology and Digital Health Article / Publication / CGM Best Practices
CGM initiation at hospital discharge is a practical way to support safer transitions of care, improve post-discharge glycemic management, and reduce preventable healthcare utilization. Early experience with structured protocols shows this approach is feasible and well-received by both patients and providers. This article shares an implementation pathway adapted from the Johns Hopkins Medicine CGM Hospital Discharge protocol.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Initiation and persistence of CGM use (>270 days/year) was associated with a significantly greater A1c reduction at 12 months (-1.52%) versus no CGM, regardless of therapy. Adding a GLP-1, SGLT2i, or insulin with CGM resulted in additional significant A1c reduction. These results highlight the broad benefits of sustained CGM use across different medication types, including for individuals not using insulin.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Early detection and management of gestational diabetes (GDM) benefits both mother and infants. For women with early GDM, Dexcom CGM improved maternal and neonatal complications, including lower unscheduled caesarean sections, preterm deliveries, large-for-gestational age neonates, and NICU admissions, compared to self-monitoring of blood glucose (SMBG).
LEARN MOREThe future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
October 20, 2025Population Health Article / Publication / Population Health
The article explores how expanding access to continuous glucose monitoring (CGM) for individuals with type 2 diabetes—especially those not using insulin—can lead to improved clinical outcomes and reduced healthcare costs. It presents peer-led best practices and underscores the value of integrating CGM into primary care, supported by real-world evidence. It highlights some of the latest evidence highlighting CGM’s benefits in lowering emergency department visits and optimizing medication use, while advocating for broader coverage and streamlined access to diabetes technology.
LEARN MOREImproved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Continuous Glucose Monitoring at Hospital Discharge: Evidence, Implementation, and Value for Health Systems
This AJMC Profiles in Care article highlights best practices and real‑world insights from health systems implementing CGM at hospital discharge, including early clinical and operational outcomes relevant to payers and health system decision‑makers.
LEARN MOREExploratory Study of Selected Stakeholder Insights Into Continuous Glucose Monitoring in T2D With Risk-Sharing Agreements
December 17, 2025Coverage and Benefit Design Article / Publication
The article highlights how expanding access to continuous glucose monitoring (CGM) within risk-sharing agreements can improve glycemic outcomes and support value-based diabetes care, particularly for patients with poorly controlled type 2 diabetes. Real-world data from Ohio demonstrated rapid HbA1c reductions and high HEDIS target attainment when CGM was paired with reduced prior authorization and interdisciplinary care. An expert payer-provider panel recommended focusing risk-based CGM programs on non–insulin-treated patients with HbA1c >8%, using HbA1c and emerging CGM-derived metrics for performance measurement, and leveraging team-based models to reduce utilization and address health equity.
LEARN MOREDecember 17, 2025CGM Technology and Digital Health Article / Publication / CGM Best Practices
CGM initiation at hospital discharge is a practical way to support safer transitions of care, improve post-discharge glycemic management, and reduce preventable healthcare utilization. Early experience with structured protocols shows this approach is feasible and well-received by both patients and providers. This article shares an implementation pathway adapted from the Johns Hopkins Medicine CGM Hospital Discharge protocol.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Initiation and persistence of CGM use (>270 days/year) was associated with a significantly greater A1c reduction at 12 months (-1.52%) versus no CGM, regardless of therapy. Adding a GLP-1, SGLT2i, or insulin with CGM resulted in additional significant A1c reduction. These results highlight the broad benefits of sustained CGM use across different medication types, including for individuals not using insulin.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Early detection and management of gestational diabetes (GDM) benefits both mother and infants. For women with early GDM, Dexcom CGM improved maternal and neonatal complications, including lower unscheduled caesarean sections, preterm deliveries, large-for-gestational age neonates, and NICU admissions, compared to self-monitoring of blood glucose (SMBG).
LEARN MOREThe future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
October 20, 2025Population Health Article / Publication / Population Health
The article explores how expanding access to continuous glucose monitoring (CGM) for individuals with type 2 diabetes—especially those not using insulin—can lead to improved clinical outcomes and reduced healthcare costs. It presents peer-led best practices and underscores the value of integrating CGM into primary care, supported by real-world evidence. It highlights some of the latest evidence highlighting CGM’s benefits in lowering emergency department visits and optimizing medication use, while advocating for broader coverage and streamlined access to diabetes technology.
LEARN MOREImproved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Exploratory Study of Selected Stakeholder Insights Into Continuous Glucose Monitoring in T2D With Risk-Sharing Agreements
The article highlights how expanding access to continuous glucose monitoring (CGM) within risk-sharing agreements can improve glycemic outcomes and support value-based diabetes care, particularly for patients with poorly controlled type 2 diabetes. Real-world data from Ohio demonstrated rapid HbA1c reductions and high HEDIS target attainment when CGM was paired with reduced prior authorization and interdisciplinary care. An expert payer-provider panel recommended focusing risk-based CGM programs on non–insulin-treated patients with HbA1c >8%, using HbA1c and emerging CGM-derived metrics for performance measurement, and leveraging team-based models to reduce utilization and address health equity.
LEARN MOREDecember 17, 2025CGM Technology and Digital Health Article / Publication / CGM Best Practices
CGM initiation at hospital discharge is a practical way to support safer transitions of care, improve post-discharge glycemic management, and reduce preventable healthcare utilization. Early experience with structured protocols shows this approach is feasible and well-received by both patients and providers. This article shares an implementation pathway adapted from the Johns Hopkins Medicine CGM Hospital Discharge protocol.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Initiation and persistence of CGM use (>270 days/year) was associated with a significantly greater A1c reduction at 12 months (-1.52%) versus no CGM, regardless of therapy. Adding a GLP-1, SGLT2i, or insulin with CGM resulted in additional significant A1c reduction. These results highlight the broad benefits of sustained CGM use across different medication types, including for individuals not using insulin.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Early detection and management of gestational diabetes (GDM) benefits both mother and infants. For women with early GDM, Dexcom CGM improved maternal and neonatal complications, including lower unscheduled caesarean sections, preterm deliveries, large-for-gestational age neonates, and NICU admissions, compared to self-monitoring of blood glucose (SMBG).
LEARN MOREThe future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
October 20, 2025Population Health Article / Publication / Population Health
The article explores how expanding access to continuous glucose monitoring (CGM) for individuals with type 2 diabetes—especially those not using insulin—can lead to improved clinical outcomes and reduced healthcare costs. It presents peer-led best practices and underscores the value of integrating CGM into primary care, supported by real-world evidence. It highlights some of the latest evidence highlighting CGM’s benefits in lowering emergency department visits and optimizing medication use, while advocating for broader coverage and streamlined access to diabetes technology.
LEARN MOREImproved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
CGM initiation at hospital discharge is a practical way to support safer transitions of care, improve post-discharge glycemic management, and reduce preventable healthcare utilization. Early experience with structured protocols shows this approach is feasible and well-received by both patients and providers. This article shares an implementation pathway adapted from the Johns Hopkins Medicine CGM Hospital Discharge protocol.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Initiation and persistence of CGM use (>270 days/year) was associated with a significantly greater A1c reduction at 12 months (-1.52%) versus no CGM, regardless of therapy. Adding a GLP-1, SGLT2i, or insulin with CGM resulted in additional significant A1c reduction. These results highlight the broad benefits of sustained CGM use across different medication types, including for individuals not using insulin.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Early detection and management of gestational diabetes (GDM) benefits both mother and infants. For women with early GDM, Dexcom CGM improved maternal and neonatal complications, including lower unscheduled caesarean sections, preterm deliveries, large-for-gestational age neonates, and NICU admissions, compared to self-monitoring of blood glucose (SMBG).
LEARN MOREThe future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
October 20, 2025Population Health Article / Publication / Population Health
The article explores how expanding access to continuous glucose monitoring (CGM) for individuals with type 2 diabetes—especially those not using insulin—can lead to improved clinical outcomes and reduced healthcare costs. It presents peer-led best practices and underscores the value of integrating CGM into primary care, supported by real-world evidence. It highlights some of the latest evidence highlighting CGM’s benefits in lowering emergency department visits and optimizing medication use, while advocating for broader coverage and streamlined access to diabetes technology.
LEARN MOREImproved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Initiation and persistence of CGM use (>270 days/year) was associated with a significantly greater A1c reduction at 12 months (-1.52%) versus no CGM, regardless of therapy. Adding a GLP-1, SGLT2i, or insulin with CGM resulted in additional significant A1c reduction. These results highlight the broad benefits of sustained CGM use across different medication types, including for individuals not using insulin.
LEARN MOREDecember 17, 2025Clinical Outcomes Article / Publication
Early detection and management of gestational diabetes (GDM) benefits both mother and infants. For women with early GDM, Dexcom CGM improved maternal and neonatal complications, including lower unscheduled caesarean sections, preterm deliveries, large-for-gestational age neonates, and NICU admissions, compared to self-monitoring of blood glucose (SMBG).
LEARN MOREThe future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
October 20, 2025Population Health Article / Publication / Population Health
The article explores how expanding access to continuous glucose monitoring (CGM) for individuals with type 2 diabetes—especially those not using insulin—can lead to improved clinical outcomes and reduced healthcare costs. It presents peer-led best practices and underscores the value of integrating CGM into primary care, supported by real-world evidence. It highlights some of the latest evidence highlighting CGM’s benefits in lowering emergency department visits and optimizing medication use, while advocating for broader coverage and streamlined access to diabetes technology.
LEARN MOREImproved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Early detection and management of gestational diabetes (GDM) benefits both mother and infants. For women with early GDM, Dexcom CGM improved maternal and neonatal complications, including lower unscheduled caesarean sections, preterm deliveries, large-for-gestational age neonates, and NICU admissions, compared to self-monitoring of blood glucose (SMBG).
LEARN MOREThe future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
October 20, 2025Population Health Article / Publication / Population Health
The article explores how expanding access to continuous glucose monitoring (CGM) for individuals with type 2 diabetes—especially those not using insulin—can lead to improved clinical outcomes and reduced healthcare costs. It presents peer-led best practices and underscores the value of integrating CGM into primary care, supported by real-world evidence. It highlights some of the latest evidence highlighting CGM’s benefits in lowering emergency department visits and optimizing medication use, while advocating for broader coverage and streamlined access to diabetes technology.
LEARN MOREImproved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
The future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
The article explores how expanding access to continuous glucose monitoring (CGM) for individuals with type 2 diabetes—especially those not using insulin—can lead to improved clinical outcomes and reduced healthcare costs. It presents peer-led best practices and underscores the value of integrating CGM into primary care, supported by real-world evidence. It highlights some of the latest evidence highlighting CGM’s benefits in lowering emergency department visits and optimizing medication use, while advocating for broader coverage and streamlined access to diabetes technology.
LEARN MOREImproved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Improved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn More
Dexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn More